Fulcrum Therapeutics (FULC) Operating Income (2018 - 2026)

Fulcrum Therapeutics (FULC) has reported Operating Income for 9 consecutive years, with -$29.3 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Operating Income fell 47.92% year-over-year to -$29.3 million; the TTM figure through Jun 2026 stood at -$96.0 million (down 13.3% YoY), while the FY2025 annual figure was -$84.8 million, down 287.13% from the prior year.
• Operating Income slipped to -$29.3 million in Q2 2026 per FULC's latest filing, from -$22.2 million in the prior quarter.
• Across five years, Operating Income topped out at $52.5 million in Q2 2024 and bottomed at -$34.2 million in Q2 2022.
• Historically, Operating Income has averaged -$21.2 million across 5 years, with a median of -$25.6 million in 2022.
• Annual changes were most pronounced in 2024 — Operating Income jumped 292.33% — and 2025, when it tumbled 137.75%.
• Fulcrum Therapeutics' Operating Income stood at -$28.0 million in 2022, then slipped by 0.07% to -$28.0 million in 2023, then jumped by 30.59% to -$19.4 million in 2024, then retreated by 16.8% to -$22.7 million in 2025, then declined by 29.16% to -$29.3 million in 2026.
• Business Quant data shows FULC's Operating Income at -$29.3 million in Q2 2026, -$22.2 million in Q1 2026, and -$22.7 million in Q4 2025.